CytomX Therapeutics, Inc.
↗South San Francisco, California, United States
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of conditionally activated, masked biologics designed to localize to the tumor microenvironment. Founded in 2008 from technology developed at UC Santa Barbara by Frederick Gluck, Dr. Nancy Stagliano, and Professor Patrick Daugherty, the company's proprietary PROBODY® therapeutic platform enables the development of safer, more effective cancer therapies by selectively activating in tumor tissue while remaining inactive in healthy tissue and circulation. The platform addresses previously undruggable targets and enables multiple therapeutic modalities including antibody-drug conjugates (ADCs), T-cell-engaging bispecific antibodies (TCBs), and immunomodulators such as cytokines and checkpoint inhibitors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$6M-$33M annually (partnership-driven)
Founded:2008
Ownership:public
Status:operating
FUNDING
Stage:Public (IPO 2015)
Total Raised:$136M
Investors:Fidelity Investments, Canaan Partners, Third Rock Ventures
STOCK
Exchange:NASDAQ
Ticker:CTMX
Market Cap:$721.79M
PIPELINE
Stage:Phase 1 (clinical), Preclinical (discovery collaborations)
Lead Drug Stage:Phase 1 - CX-2051 (EpCAM-targeted ADC in advanced CRC)
Modalities:Antibody-Drug Conjugates (ADCs), T-cell-engaging bispecific antibodies (TCBs), Masked cytokines, Checkpoint inhibitors
Active Trials:3
Trial Phases:Phase 1: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Amgen, AbbVie, Bristol Myers Squibb, Astellas Pharma, Regeneron, Moderna
COMPETITION
Position:Niche Leader - pioneering conditional/masked biologics platform; only EpCAM ADC in development; differentiated multi-modality approach
Competitors:Mersana Therapeutics, Aura Biosciences, Vor Biopharma, Celldex Therapeutics, Adaptimmune Therapeutics, Alentis Therapeutics, Oxford Biotherapeutics, MBrace Therapeutics +1 more
LEADERSHIP
Key Executives:
Sean A. McCarthy, D.Phil. - Chief Executive Officer and Chairman of the Board
Amy C. Peterson - Executive Vice President, Chief Development Officer
Carlos Campoy - Senior Vice President, Chief Financial Officer
Marcia P. Belvin, Ph.D. - Chief Scientific Officer
Wayne Chu, M.D. - Senior Leadership
Scientific Founders:Frederick (Fred) Gluck, Dr. Nancy E. Stagliano, Professor Patrick Daugherty
Board Members:Sean A. McCarthy, D.Phil. (Chairman/CEO), Dr. Elaine Jones (Director), James R. Meyers (Director), Dr. Mani Mohindru (Director), W. Michael Kavanaugh (Director), Matthew P. Young (Director), Halley E. Gilbert (Director), Dr. Su (Weng Su) (Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CytomX Therapeutics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.